Detalhe da pesquisa
1.
Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.
Nature
; 607(7920): 808-815, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35794478
2.
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
Blood
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38701426
3.
Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns.
Blood
; 142(6): 561-573, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37084389
4.
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
Blood
; 141(20): 2493-2507, 2023 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36302166
5.
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma.
Blood
; 141(8): 904-916, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36201743
6.
Characterization of DLBCL with a PMBL gene expression signature.
Blood
; 138(2): 136-148, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33684939
7.
Author Correction: Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.
Nature
; 611(7934): E2, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36253470
8.
The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
Blood
; 134(18): 1528-1532, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31527075
9.
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.
Int J Hematol
; 119(3): 275-290, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38285120
10.
Biological heterogeneity in diffuse large B-cell lymphoma.
Semin Hematol
; 60(5): 267-276, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38151380
11.
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Leukemia
; 37(10): 2094-2106, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37598282
12.
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 41(25): 4164-4177, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37319384
13.
Relapse timing is associated with distinct evolutionary dynamics in DLBCL.
medRxiv
; 2023 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945587
14.
Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL.
Cancer Discov
; 11(12): 2965-2967, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363869
15.
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.
Blood Adv
; 5(1): 71-83, 2021 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33570635
16.
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.
Blood Adv
; 5(15): 2945-2957, 2021 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34323958
17.
PRPS-ST: A protocol-agnostic self-training method for gene expression-based classification of blood cancers.
Blood Cancer Discov
; 1(3): 244-257, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392514
18.
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.
Blood Adv
; 4(13): 2886-2898, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589730
19.
The NIMA-related kinase NEK1 cycles through the nucleus.
Biochem Biophys Res Commun
; 389(1): 52-6, 2009 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19699716
20.
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL.
Blood Adv
; 7(20): 6156-6162, 2023 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595057